Article Text

Download PDFPDF
Unplanned pregnancy in an HIV positive woman undergoing alectinib treatment for metastatic non-small-cell lung carcinoma
  1. Séverine Carlier1,
  2. Luciano Carestia1,
  3. Jean-Christophe Marot2 and
  4. Grégoire Wieërs2,3
  1. 1Pneumology, Clinique Saint-Pierre, Ottignies, Belgium
  2. 2General Internal Medicine, Clinique Saint-Pierre Ottignies, Ottignies, Belgium
  3. 3Medicine, Université de Namur, Namur, Belgium
  1. Correspondence to Dr Grégoire Wieërs; gregoire.wieers{at}cspo.be

Abstract

We report an unplanned pregnancy in an HIV-positive woman in her 20s who was undergoing treatment for 6 months with alectinib (Alecensa) for stage IV non-small-cell lung carcinoma. Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor alectinib, a molecule that inhibits proteins involved in tumour cell growth, is the recommended first-line treatment option in case of ALK mutation. Although the patient was informed of the need for definitive contraception, she became pregnant during the treatment with alectinib. A complete tumour response was observed at the time the pregnancy was discovered. Treatment discontinuation was proposed as the patient wanted to keep the pregnancy. Alectinib was temporarily stopped throughout the remaining pregnancy period inline with the patient’s wishes. The pregnancy was uncomplicated. She delivered a healthy female baby vaginally, with treatment being resumed after delivery. After 34 follow-up months, the patient remained in oncological remission and the child’s physical development is normal.

  • Cancer intervention
  • HIV / AIDS
  • Drugs: obstetrics and gynaecology
  • Lung cancer (oncology)
  • Neonatal health

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors SC and LC took care of the patient and wrote the article. J-CM took care of the patient. GJFGW revised critically the paper and is the guarantor of the paper.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.